Skip to main content Accessibility help
×
Home

Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis

  • C G Leonard (a1), C Masih (a2), S McDonald (a2), G Taylor (a1), N Maiden (a2) and P J Leyden (a1)...

Abstract

Background:

Chronic rhinosinusitis has many risk factors; however, the effect of anti-tumour necrosis factor therapy has not been investigated in depth. Our experience points to a detrimental clinical effect in overall prevalence of chronic rhinosinusitis, despite its benefit in certain subtypes.

Method:

A telephone survey was performed to parallel the findings of the Global Allergy and Asthma European Network chronic rhinosinusitis screening survey. This was itself based on the widely recognised European Position Paper on Rhinosinusitis and Nasal Polyps criteria.

Results:

A total of 120 patients responded to the survey. The prevalence of chronic rhinosinusitis in the anti-tumour necrosis factor therapy population was 20 per cent (95 per cent confidence interval = 12.84–27.16). When compared using a chi-square test, for a two-by-two contingency table, this finding was significant against the prevalence recorded in the normal population.

Conclusion:

This is the first observational study indicating increased prevalence of chronic rhinosinusitis in patients treated with anti-tumour necrosis factor therapy. These clinical findings require investigation in greater depth to clarify the nature of pathologies currently diagnosed and treated as chronic rhinosinusitis.

Copyright

Corresponding author

Address for correspondence: Mr C G Leonard, Department of Otorhinolaryngology, Level 3 Secretary's Office, Craigavon Area Hospital, Craigavon, Northern Ireland, UK E-mail: mrcgleonard@gmail.com

References

Hide All
1 Smith, KA, Orlandi, RR, Rudmik, L. Cost of adult chronic rhinosinusitis: a systematic review. Laryngoscope 2015;125:1547–56
2 Fokkens, WJ, Lund, VJ, Mullol, J, Bachert, C, Alobid, I, Baroody, F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:112
3 Kato, A. Immunopathology of chronic rhinosinusitis. Allergol Int 2015;64:121–30
4 Hastan, D, Fokkens, WJ, Bachert, C, Newson, RB, Bislimovska, J, Bockelbrink, A et al. Chronic rhinosinusitis in Europe – an underestimated disease. A GA2LEN study. Allergy 2011;66:1216–23
5 Bhattacharyya, N, Lee, LN. Evaluating the diagnosis of chronic rhinosinusitis based on clinical guidelines and endoscopy. Otolaryngol Head Neck Surg 2010;143:147–51
6 Karosi, T, Csomor, P, Sziklai, I. Tumour necrosis factor-α receptor expression correlates with mucosal changes and biofilm presence in chronic rhinosinusitis with nasal polyposis. Laryngoscope 2012;122:504–10
7 Doran, M, Crowson, C, Pond, G, O'Fallon, W, Gabriel, S. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93
8 Ding, T, Ledingham, J, Lugmani, R, Westlake, S, Hyrich, K, Lunt, M et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010;49:2217–19
9 Maroon, M, Bond, U, Phelan, M. Sinusitis: a possible link with adalimumab. Clin Rheumatol 2008;27:1189–90
10 Tezuka, H, Abe, Y, Iwata, M, Takeuchi, H, Ishikawa, H, Matsushita, M et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 2007;448:929–33

Keywords

Anti-tumour necrosis factor therapy is associated with certain subtypes of chronic rhinosinusitis

  • C G Leonard (a1), C Masih (a2), S McDonald (a2), G Taylor (a1), N Maiden (a2) and P J Leyden (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed